19 October-1 December 2020
The 51st Union World Conference On Lung Health
REGISTER NOW

Sessions

All Sessions
keyboard_arrow_down
keyboard_arrow_down Show filters keyboard_arrow_up Hide filters
  • All Tracks
  • Community Connect
  • Channel 1
  • Channel 2
  • Channel 3
  • Channel 4
  • Channel 5
  • Channel 6
  • Channel 7
  • E-posters
  • Workshops
E-posters
EP16-TB: new insights on cost and cost-effectiveness
event_note
Loading...
query_builder 10:00 - 11:00 | Event time (GMT+2)
query_builder - | Your time (GMT)
place Online Session/Virtual
card_travel E-poster session
mic English
EP16-TB: new insights on cost and cost-effectiveness
*Please scroll down for more information*
All E-posters are accessible via the "E-posters" section of the conference platform until 30 November.

EP16-251-22-Standardised framework for evaluating the cost-effectiveness of TB case finding and treatment initiation projectsInterventions that streamline and reduce gaps in the tuberculosis (TB) care cascade can play crucial roles in TB control efforts. However, such interventions are often operationally complex and resource intensive. There is a need to better understand their costs and cost-effectiveness to support decisions for future funding, strategic adoption and programme scale-up.
Isabella Gomes

EP16-252-22-Interferon gamma release assay is a cost-effective option for provision of TB preventive therapy in high-burden, resource-limited settingsCost-effectiveness analysis is needed to inform the adoption of interferon gamma release assay (IGRA) for diagnosing latent tuberculosis (TB) in resource-limited settings. A feasibility study in Uganda shows that IGRA is cost-effective per TB disease and infection averted and, therefore, a viable option for resource-limited settings.
Simon Muchuro

EP16-253-22-Pretreatment costs for TB patients: results from an observational cohort study in Johannesburg, South AfricaTuberculosis (TB) patients the world over are faced not only with the infection itself, but also the medical and non-medical costs associated with seeking care. This abstract describes the direct (out-of-pocket) payment that patients incur before TB treatment initiation as well as highlights the sequence of providers seen.
Kamban Hirasen

EP16-254-22-The costs of providing TB services in healthcare facilities in Kenya: a case for investment to end TBThe Kenyan National Tuberculosis (TB), Leprosy and Lung Disease Program conducted a comprehensive costing study for tuberculosis (TB) service delivery. The unit costs for all TB interventions and services will inform future budgeting processes and national strategic planning in Kenya.
Angela Kairu

EP16-255-22-The cost of reaching agricultural workers for TB prevention and treatment services in South AfricaGiven occupational exposures and distances from health facilities, agricultural workers are at special risk for tuberculosis (TB) in South Africa. We implemented a community and workplace-based outreach, screening and adherence support intervention. This model offers a cost-efficient solution for active case finding among key populations.
Alexander Moran

EP16-256-22-Cost-effectiveness analysis of three tuberculosis (TB) case detection methods implemented in South West Nigeria State of Lagos, Oyo and OsunIt is a cross-sectional study designed to evaluate the cost-effectiveness of three different tuberculosis (TB) case detection methods in South West Nigeria. Household contact tracing with routine passive case detection is the most cost-effective approach to detect new TB cases, compared with house-to-house campaign and private facility incentive methods.
Muse Olatunbosun Fadeyi

EP16-257-22-An evaluation of the feasibility and costs associated with a private sector engagement pilot for pharmacies in Ho Chi Minh City, Viet NamPharmacies represent the initial care seeking point for a large proportion of people with tuberculosis (TB), yet this category of providers had not been systematically engaged in Viet Nam. We evaluated the feasibility and costs of a pharmacy engagement pilot which used the SwipeRx social networking app to make diagnostic referrals.
Tran Phuong TM

EP16-258-22-Cost-effectiveness analysis of nine-month MDR-TB treatment regimen as evaluated within the STREAM trial. Further presentation of differences in food supplement spending and working hours disaggregated by sexThe STREAM 1 trial demonstrated that the short regimen reduced health system costs and was associated with an earlier return to work and a reduction in supplementary food spending. We are now presenting the food supplement and working hours data, dissagregated by sex, and the probabilistic estimates of the likelihood that the short regimen is cost-effective.
Laura Rosu

EP16-259-22-Cost analysis of the diagnostic cascade among patients with presumed pulmonary TB searching for care at a public health centre in Rio de Janeiro, BrazilThe reduction of socioeconomic inequities is a priority for the elimination of tuberculosis (TB).  We aimed to analyse the direct and indirect costs incurred in the diagnosis of pulmonary TB among patients with presumed TB searching for care at a public health centre in Rio de Janeiro, Brazil.     
Adriana da Silva Rezende Moreira

EP16-260-22-Setting chest X-ray abnormality thresholds to conduct validation of artificial intelligence vendors and ensure targeted and cost-effective GeneXpert testing for abnormal X-ray personsIn settings where artificial intelligence (AI) is used as a screening aid, the probability of having tuberculosis (TB) determines if a patient will be referred for GeneXpert testing. Setting the right probability threshold can validate AI software and ensure the minimum number of tests are conducted to find the maximum number of patients.
Akash Malhotra

EP16-261-22-Charging user fees is not a predictor of the number of TB cases detected among private health facilities in NigeriaThe United States Agency for International Development's (USAID) Plus SHOPS (Sustaining Health Outcomes through Private Sector) Nigeria initiative supports screening and testing tuberculosis (TB) clients in clinical facilities to increase access to care through the private sector. Facilities are allowed to charge for care. We hypothesised that charging fees is not associated with higher/lower TB case detection and used programme data to validate.
Bolanle Olusola-Faleye

EP16-262-22-Cost-effectiveness analysis of proposed TB diagnostic algorithm using the loop-mediated isothermal amplification among presumptive TB patients in the PhilippinesThis paper is an economic evaluation study of different diagnostic tools used among healthcare facilities under the tuberculosis (TB) control programme in the Philippines. DSSM as the conventional method, GeneXpert a rapid molecular test and PURE-TB LAMP (loop-mediated isothermal amplification) as a novel molecular point of care test.
Rosarie Villabito Gabuya

Loading...
E-posters
EP28-Making the most of short money to fight TB
event_note
Loading...
query_builder 10:00 - 11:00 | Event time (GMT+2)
query_builder - | Your time (GMT)
place Online Session/Virtual
card_travel E-poster session
mic English
EP28-Making the most of short money to fight TB
*Please scroll down for more information*
All E-posters are accessible via the "E-posters" section of the conference platform until 30 November.

EP28-364-23-Examining the cost of delivering TB prevention, diagnosis and treatment in the Philippines, 2018The Philippines tuberculosis (TB) programme conducted a national study to establish the cost of TB service delivery following recent standards. Unit costs for 21 TB interventions and 39 technologies in 2018, better equip planners to understand cost variations across facility type, urbanicity and ownership, to inform the provision of people-centred, affordable services.
Inés Garcia Baena

EP28-365-23-Examining the cost of delivering TB prevention, diagnosis and treatment in India, 2018Unit cost data is important for planning and priority setting for a programme. However, there is paucity of such data for tuberculosis (TB) in India. This study estimated unit costs of key services related to TB, from a provider perspective, using data from 20 health facilities in two states in India.  
Susmita Chatterjee

EP28-366-23-First national TB patient cost survey in Lao PDR: assessment of the financial burden faced by TB-affected households and comparisons by drug-susceptibility and HIV statusLao PDR National TB Programme conducted the first national tuberculosis (TB) patient cost survey in 2018-2019 to assess the magnitude of the financial burden, due to TB, and the percentage of TB-affected households facing catastrophic costs. The survey focused on sampling drug-resistant TB and TB-HIV patients, in addition to nationally representative samples.
Takuya Yamanaka

EP28-367-23-Economic evaluation of patient costs associated with TB diagnosis and care in Papua New GuineaEconomic burden incurred by tuberculosis (TB) patients and their households due to TB disease can affect patients’ adherence and outcomes and increase the risk of TB transmission. A national survey has been conducted in Papua New Guinea to evaluate the magnitude and main drivers of these costs.
Margaret Kal

EP28-368-23-Catastrophic costs for TB patients before treatment starts: results from a multicountry, observational cohort study in sub-Saharan AfricaIn attempting to contextualise and quantify the cost burden of tuberculosis (TB) to individuals and households, the World Health Organization, through the End TB Strategy, introduced a TB-specific indicator of economic risk called ‘catastrophic costs’. We use different approaches to determine the proportion of TB patients facing catastrophic costs during pre-treatment TB care.
Kamban Hirasen

EP28-369-23-Financial risk protection benefits of expanded TB control interventions in Ethiopia: an extended, cost-effectiveness analysis modelling studyWe used models to estimate reductions in tuberculosis (TB) related catastrophic costs with aggressive expansion of TB services in Ethiopia from 2017 to 2035. Improvement in the delivery of TB services may substantially reduce the catastrophic cost burden on affected households.
Lelisa Fekadu Assebe

EP28-370-23-Cost-effectiveness of nutritional supplementation to decrease TB incidence and mortality in IndiaAt least one in three tuberculosis (TB) cases in India are attributable to undernutrition. Addressing undernutrition is, therefore, crucial to achieve the Indian government’s aim of eliminating TB. We describe a modelling approach to assess cost-effectiveness of nutritional supplementation to prevent TB cases and deaths.
Pranay Sinha

EP28-371-23-Modelling the impact of a bedaquiline-containing short-course regimen on cost and disease burden of drug-resistant TB in the PhilippinesThis study explores the comparative benefits of the optimal implementation of the World Health Organization's recommended drug-resistant tuberculosis (TB) treatment using a bedaquiline-containing, short-course regimen in the Philippines. It explored the benefits, set alongside using established injectable-containing regimens, on reduction in disease burden, healthcare cost burden and aversion of disability-adjusted life years over 2020-2040.
Mpobela Abela Agnarson

EP28-372-23-The potential value of biomarker-led preventive therapy in eliminating TB: a modelling analysisNovel biomarker signatures offer prognostic value in identifying individuals at imminent risk of developing active tuberculosis (‘incipient’ TB). Using a mathematical model of TB transmission in Chennai, India, we examine whether such tools offer cost-effective approaches for TB control in a high burden setting.
Saskia Ricks

EP28-373-23-Do evaluations of Tuberculosis Active Case Finding report estimates of resource need? A review of the evidenceActive case finding (ACF) interventions aim to improve early TB case detection and prevent transmission of infection- but what resources are needed to run an ACF intervention, and are these routinely reported in evaluations? We review 65 ACF interventions for their reporting on resource needs.
Madeleine Clarkson

EP28-374-23-Estimating the value-based price of new TB vaccines in India and ChinaWe estimate the value-based price of new tuberculosis (TB) vaccines in China and India using a dynamic transmission mathematical model of TB and rifampicin-resistant and multidrug-resistant tuberculosis (RR/MDR-TB), attached to a country specific cost model. We incorporate epidemiologic uncertainty and uncertainty in cost of delivery of TB and vaccine services into our estimates.
Chathika Weerasuriya

EP28-375-23-Optimising investments in Mozambique’s TB response: results of a TB Optima modelling studyTo achieve the goal of ending tuberculosis (TB), it is crucial to determine which models of TB care and treatment should be prioritised, especially in the context of limited resources. The team used Optima TB, a mathematical model of TB transmission and disease progression, integrated with an economic and programme analysis framework.
Pereira Zindoga

Loading...
Channel 3
OA-29-Who pays the cheque? The economic burden of TB
event_note
Loading...
query_builder 15:00 - 16:20 | Event time (GMT+2)
query_builder - | Your time (GMT)
place Online Session/Virtual
card_travel Oral Abstract session
mic English
OA-29-Who pays the cheque? The economic burden of TB
*Please scroll down for more information*


15:00 - 15:05: Introduction


15:05 - 15:13: OA-29-680-23-Assessing the economic impact of TB mortality in 165 countries: what it will cost if we don’t achieve the End TB targets Tuberculosis (TB) elimination leads to colossal health and development returns. However, evidence on the economics of ending TB remains disparate. We estimate the economic dividend of achieving the End TB mortality target by 2030 and the cost of inaction - the welfare penalty - of not meeting the target until 2045.

Sachin Silva

15:13 - 15:21: OA-29-681-23-First national survey of the costs borne by households with TB in the Democratic Republic of the Congo 2019 The Democratic Republic of the Congo tuberculosis (TB) programme conducted its first national TB patient cost survey in 2019 to establish a baseline for monitoring the progress towards elimination of catastrophic costs, in line with World Health Organization methods. National health and social policy interventions, geared to mitigate newly evidenced economic burden borne by TB patients, require crafting.

Inés Garcia Baena

15:21 - 15:29: OA-29-682-23-Determinants of household catastrophic costs for TB care in Kenya Despite the significant burden of drug-sensitive tuberculosis (DS-TB) cases, little is known about the predictors for catastrophic costs among them. This presentation will share results on the determinants for household catastrophic costs among DS-TB patients in Kenya. This could be the first step in designing tailor-made social interventions.

Beatrice Kirubi

15:29 - 15:37: OA-29-683-23-Economic burden of TB in Tanzania: a national survey of costs faced by TB-affected households Despite free provision of tuberculosis (TB) care, TB-related costs can be overwhelming and sometimes catastrophic for patients and their households, leading to poor treatment adherence and patient outcomes. We conducted a national survey to assess the economic burden of TB on patients and their households in Tanzania in 2019.

Andrew Martin Kilale

15:37 - 15:45: OA-29-684-23-Direct medical costs and out-of-pocket expenditures on TB treatment in three regions of China Although tuberculosis (TB) treatment is free of charge in China, medical costs during the inpatient treatment period still resulted in more than 10% of TB-affected families facing catastrophic costs. During outpatient treatment, the proportion of out-of-pocket expenditures reached almost 50% of direct medical costs because of additional medicines for drug-induced adverse effects.

Xubin Zheng

15:45 - 15:53: OA-29-685-23-Catastrophic costs associated with diagnostic cascade and treatment of TB among patients treated at a public health centre in Rio de Janeiro, Brazil Poor socioeconomic conditions increase the risk for tuberculosis (TB) infection, reactivation and maintenance of TB in the community. We conducted a study involving patients undergoing TB treatment in a municipal health centre in Rio de Janeiro aiming to assess the direct, indirect and catastrophic costs incurred for patients with TB.

Adriana da Silva Rezende Moreira

15:53 - 16:01: OA-29-686-23-Why Cepheid Xpert MTB/RIF and SARS-CoV-2 cartridges should not be sold to low- and middle-income countries at more than $5 per test An independent cost-of-goods analysis of Cepheid’s GeneXpert MTB/RIF and HIV viral load cartridges, currently priced at $9.98 and $14.90 for low- and middle-income countries, indicates that one cartridge can be produced below $5 and can be sold, with profit, for between $5 and $7, including service and maintenance.

Stijn Deborggraeve

16:01 - 16:09: OA-29-687-23-The cost of TB contact investigation in Uganda Tuberculosis (TB) contact investigation has been recommended for a long time. However, it is not being fully implemented in most low- and middle-income countries. One of the main issues raised for this is the cost. We set out to find the cost relative to GDP and we found it to be high.

Michael Kakinda

16:09 - 16:20: Q&A


Loading...
Processing. Please wait.
Loading...